File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Pathogenesis of primary Sjögren's syndrome beyond B lymphocytes

TitlePathogenesis of primary Sjögren's syndrome beyond B lymphocytes
Authors
Issue Date2020
PublisherPacini Editore Srl. The Journal's web site is located at http://www.clinexprheumatol.org
Citation
Clinical and Experimental Rheumatology, v. 38 n. 4, suppl. 126, p. 315-323 How to Cite?
AbstractPrimary Sjögren's syndrome (pSS) is a chronic autoimmune disorder affecting exocrine glands of the body, prevalently lacrimal and salivary glands. The pSS pathogenesis has been thought to be B-cell-centric and several clinical trials have been carried out in order to clarify the therapeutic role of B-cell depletion in patients with pSS. Unfortunately, however, B-cell depletion with rituximab has failed in demonstrating any significant results in pSS patients. Besides the contribution of B cells in the pathogenesis of pSS, effector Tfh, Th17 and Th22 cells, follicular dendritic cells (DCs), innate cells (ICs) and several cytokines, chemokines and miRNA have been proved to participate to the development of this systemic disease. Understanding these molecular processes may help guide research into resistant diseases and highly targeted therapeutic strategies. This review aims to discuss important pathogenetic mechanisms involved in the initiation and perpetuation of pSS behind the established role of B cells.
DescriptionThird Annual Supplement on Sjögren’s syndrome
Persistent Identifierhttp://hdl.handle.net/10722/294201
ISSN
2023 Impact Factor: 3.4
2023 SCImago Journal Rankings: 0.907

 

DC FieldValueLanguage
dc.contributor.authorFasano, S-
dc.contributor.authorMauro, D-
dc.contributor.authorMacaluso, F-
dc.contributor.authorXiao, F-
dc.contributor.authorZhao, Y-
dc.contributor.authorLu, L-
dc.contributor.authorGuggino, G-
dc.contributor.authorCiccia, F-
dc.date.accessioned2020-11-23T08:27:52Z-
dc.date.available2020-11-23T08:27:52Z-
dc.date.issued2020-
dc.identifier.citationClinical and Experimental Rheumatology, v. 38 n. 4, suppl. 126, p. 315-323-
dc.identifier.issn0392-856X-
dc.identifier.urihttp://hdl.handle.net/10722/294201-
dc.descriptionThird Annual Supplement on Sjögren’s syndrome-
dc.description.abstractPrimary Sjögren's syndrome (pSS) is a chronic autoimmune disorder affecting exocrine glands of the body, prevalently lacrimal and salivary glands. The pSS pathogenesis has been thought to be B-cell-centric and several clinical trials have been carried out in order to clarify the therapeutic role of B-cell depletion in patients with pSS. Unfortunately, however, B-cell depletion with rituximab has failed in demonstrating any significant results in pSS patients. Besides the contribution of B cells in the pathogenesis of pSS, effector Tfh, Th17 and Th22 cells, follicular dendritic cells (DCs), innate cells (ICs) and several cytokines, chemokines and miRNA have been proved to participate to the development of this systemic disease. Understanding these molecular processes may help guide research into resistant diseases and highly targeted therapeutic strategies. This review aims to discuss important pathogenetic mechanisms involved in the initiation and perpetuation of pSS behind the established role of B cells.-
dc.languageeng-
dc.publisherPacini Editore Srl. The Journal's web site is located at http://www.clinexprheumatol.org-
dc.relation.ispartofClinical and Experimental Rheumatology-
dc.titlePathogenesis of primary Sjögren's syndrome beyond B lymphocytes-
dc.typeConference_Paper-
dc.identifier.emailXiao, F: xiaof@hku.hk-
dc.identifier.emailLu, L: liweilu@hku.hk-
dc.identifier.authorityLu, L=rp00477-
dc.identifier.pmid33095148-
dc.identifier.hkuros319901-
dc.identifier.volume38-
dc.identifier.issue4, suppl. 126-
dc.identifier.spage315-
dc.identifier.epage323-
dc.publisher.placeItaly-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats